Halozyme Therapeutics, Inc. (HALO)
67.37
+0.01
(+0.01%)
USD |
NASDAQ |
Mar 06, 16:00
67.98
+0.61
(+0.91%)
After-Hours: 20:00
Halozyme Therapeutics Cash from Investing (Quarterly) : -741.79M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Johnson & Johnson | -4.485B |
| Skye Bioscience, Inc. | 7.967M |
| AIM ImmunoTech, Inc. | 0.296M |
| Stryker Corp. | -305.00M |
| Glaukos Corp. | -15.89M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 219.03M |
| Cash from Financing (Quarterly) | 239.52M |
| Free Cash Flow | 644.59M |
| Free Cash Flow Per Share (Quarterly) | 1.849 |
| Free Cash Flow to Equity (Quarterly) | -448.84M |
| Free Cash Flow to Firm (Quarterly) | 224.50M |
| Free Cash Flow Yield | 7.80% |